Literature DB >> 25071341

Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier.

Shui-Jiao Chen1, Xiao-Wei Liu1, Jian-Ping Liu1, Xi-Yan Yang1, Fang-Gen Lu1.   

Abstract

To reduce medication for patients with ulcerative colitis (UC), we need to establish the etiology of UC. The intestinal microbiota of patients with inflammatory bowel disease (IBD) has been shown to differ from that of healthy controls and abundant data indicate that it changes in both composition and localization. Small intestinal bacterial overgrowth is significantly higher in IBD patients compared with controls. Probiotics have been investigated for their capacity to reduce the severity of UC. The luminal surfaces of the gastrointestinal tract are covered by a mucus layer. This normally acts as a barrier that does not allow bacteria to reach the epithelial cells and thus limits the direct contact between the host and the bacteria. The mucus layer in the colon comprises an inner layer that is firmly adherent to the intestinal mucosa, and an outer layer that can be washed off with minimal rinsing. Some bacteria can dissolve the protective inner mucus layer. Defects in renewal and formation of the inner mucus layer allow bacteria to reach the epithelium and have implications for the causes of colitis. In this review, important elements of UC pathology are thought to be the intestinal bacteria, gut mucus, and the mucosa-associated immune system.

Entities:  

Keywords:  Bacteria; Etiology; Infection; Mucus; Ulcerative colitis

Mesh:

Substances:

Year:  2014        PMID: 25071341      PMCID: PMC4110578          DOI: 10.3748/wjg.v20.i28.9468

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  99 in total

1.  Genetic drift. "Omics"as the filtering gateway between environment and phenotype: The inflammatory bowel diseases example.

Authors:  Richard Kellermayer
Journal:  Am J Med Genet A       Date:  2010-12       Impact factor: 2.802

2.  Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls.

Authors:  L K Vigsnæs; J Brynskov; C Steenholdt; A Wilcks; T R Licht
Journal:  Benef Microbes       Date:  2012-12-01       Impact factor: 4.205

3.  Lipopolysaccharide induces overexpression of MUC2 and MUC5AC in cultured biliary epithelial cells: possible key phenomenon of hepatolithiasis.

Authors:  Yoh Zen; Kenichi Harada; Motoko Sasaki; Koichi Tsuneyama; Kazuyoshi Katayanagi; Yui Yamamoto; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

4.  Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease.

Authors:  Wei Wang; Liping Chen; Rui Zhou; Xiaobing Wang; Lu Song; Sha Huang; Ge Wang; Bing Xia
Journal:  J Clin Microbiol       Date:  2013-11-13       Impact factor: 5.948

5.  Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis.

Authors:  Toshifumi Ohkusa; Tsutomu Yoshida; Nobuhiro Sato; Sumio Watanabe; Hisao Tajiri; Isao Okayasu
Journal:  J Med Microbiol       Date:  2009-05       Impact factor: 2.472

Review 6.  Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.

Authors:  Charlotte Hedin; Kevin Whelan; James O Lindsay
Journal:  Proc Nutr Soc       Date:  2007-08       Impact factor: 6.297

7.  Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease.

Authors:  Ben Willing; Jonas Halfvarson; Johan Dicksved; Magnus Rosenquist; Gunnar Järnerot; Lars Engstrand; Curt Tysk; Janet K Jansson
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

8.  Lactobacillus reuteri maintains a functional mucosal barrier during DSS treatment despite mucus layer dysfunction.

Authors:  Johan Dicksved; Olof Schreiber; Ben Willing; Joel Petersson; Sara Rang; Mia Phillipson; Lena Holm; Stefan Roos
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

9.  Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota.

Authors:  Samah O Noor; Karyn Ridgway; Louise Scovell; E Katherine Kemsley; Elizabeth K Lund; Crawford Jamieson; Ian T Johnson; Arjan Narbad
Journal:  BMC Gastroenterol       Date:  2010-11-12       Impact factor: 3.067

10.  Long-term alteration of intestinal microbiota in patients with ulcerative colitis by antibiotic combination therapy.

Authors:  Shigeo Koido; Toshifumi Ohkusa; Takayuki Kajiura; Junko Shinozaki; Manabu Suzuki; Keisuke Saito; Kazuki Takakura; Shintaro Tsukinaga; Shunichi Odahara; Toyokazu Yukawa; Jimi Mitobe; Mikio Kajihara; Kan Uchiyama; Hiroshi Arakawa; Hisao Tajiri
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

View more
  19 in total

1.  Oral Manifestations of Inflammatory Bowel Diseases: Two Case Reports.

Authors:  Manoela Seadi Pereira; Maria Cristina Munerato
Journal:  Clin Med Res       Date:  2016-02-10

2.  Lactobacillus rhamnosus GG treatment improves intestinal permeability and modulates inflammatory response and homeostasis of spleen and colon in experimental model of Pseudomonas aeruginosa pneumonia.

Authors:  Ludmila Khailova; Christine H Baird; Aubri A Rush; Christopher Barnes; Paul E Wischmeyer
Journal:  Clin Nutr       Date:  2016-10-01       Impact factor: 7.324

Review 3.  The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.

Authors:  Sunil Thomas; Jacques Izard; Emily Walsh; Kristen Batich; Pakawat Chongsathidkiet; Gerard Clarke; David A Sela; Alexander J Muller; James M Mullin; Korin Albert; John P Gilligan; Katherine DiGuilio; Rima Dilbarova; Walker Alexander; George C Prendergast
Journal:  Cancer Res       Date:  2017-03-14       Impact factor: 12.701

4.  Baicalin alleviates TNBS-induced colitis by inhibiting PI3K/AKT pathway activation.

Authors:  Lei Zhu; Hong Shen; Pei-Qing Gu; Ya-Jun Liu; Lu Zhang; Jia-Fei Cheng
Journal:  Exp Ther Med       Date:  2020-05-06       Impact factor: 2.447

Review 5.  Engineering the Mucus Barrier.

Authors:  T L Carlson; J Y Lock; R L Carrier
Journal:  Annu Rev Biomed Eng       Date:  2018-06-04       Impact factor: 9.590

Review 6.  Mucin glycan foraging in the human gut microbiome.

Authors:  Louise E Tailford; Emmanuelle H Crost; Devon Kavanaugh; Nathalie Juge
Journal:  Front Genet       Date:  2015-03-19       Impact factor: 4.599

Review 7.  Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review.

Authors:  Margret I Moré; Alexander Swidsinski
Journal:  Clin Exp Gastroenterol       Date:  2015-08-14

Review 8.  Innate Sensing of the Gut Microbiota: Modulation of Inflammatory and Autoimmune Diseases.

Authors:  Aline Ignacio; Camila Ideli Morales; Niels Olsen Saraiva Câmara; Rafael Ribeiro Almeida
Journal:  Front Immunol       Date:  2016-02-19       Impact factor: 7.561

9.  The Promise of Patient-Derived Colon Organoids to Model Ulcerative Colitis.

Authors:  Babajide A Ojo; Kelli L VanDussen; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2022-02-01       Impact factor: 7.290

Review 10.  Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut.

Authors:  Andrea Michielan; Renata D'Incà
Journal:  Mediators Inflamm       Date:  2015-10-25       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.